Clinical Trial Update: Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating glucagon-like peptide-1 (GLP-1) agonists for cognitive dysfunction in bipolar disorder and major depressive disorder has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Snippet

Sponsor: University Health Network, Toronto | Conditions: Bipolar Disorder, Major Depressive Disorder | Phase 3 | Status: COMPLETED